Literature DB >> 25300229

Reproducibility of histological subtyping of malignant pleural mesothelioma.

Luka Brčić1, Marko Jakopović, Iva Brčić, Vlasta Klarić, Milan Milošević, Ana Sepac, Miroslav Samaržija, Sven Seiwerth.   

Abstract

Malignant pleural mesothelioma (MPM) has a very poor prognosis. Although clinical stage is currently the only reliable prognostic factor, histologic subtyping reportedly also affects prognosis. Some studies propose reclassification of pleomorphic epithelioid as biphasic or sarcomatoid MPM. This study assessed prognostic significance and interobserver agreement in MPM subtyping of small biopsy specimens. We analyzed biopsy specimens, and clinical and survival data from records of 108 patients who were diagnosed between 2000 and 2010 at the Institute of Pathology University of Zagreb School of Medicine, of whom 98 had epithelioid MPM, six biphasic MPM, and four sarcomatoid MPM. Among epithelioid subtypes, 44 (44.9 %) were solid, 19 (19.4 %) tubulopapillary, 18 (18.4 %) acinar, six (6.1 %) adenomatoid, five (5.1 %) pleomorphic, four (4.1 %) trabecular, and two (2.0 %) micropapillary subtype. Interobserver reliability for histological diagnosis was found to be κ = 0.72 (P < 0.001). Median overall survival for epithelioid MPM was 10.5 months with an interquartile range (IQR) of 5.8-28.0 months but significantly shorter for the pleomorphic subtype (3 [IQR 3.0-8.0] months; P = 0.034), but not significantly different from biphasic (6.5 [IQR 3.5-15.3] months) and sarcomatoid mesothelioma (4.0 [IQR 1.3-6.8] months; P = 0.270). We found strong reproducibility of MPM subtyping with good interobserver agreement. Furthermore, our results indicate that pleomorphic subtype to be a predictor of poor prognosis and support classifying it with sarcomatoid or biphasic MPM, as patients with the pleomorphic, biphasic, or sarcomatoid subtype show similarly poor overall survival.

Entities:  

Mesh:

Year:  2014        PMID: 25300229     DOI: 10.1007/s00428-014-1664-9

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  23 in total

1.  Histologic assessment and prognostic factors of malignant pleural mesothelioma treated with extrapleural pneumonectomy.

Authors:  Andrea V Arrossi; E Lin; David Rice; Cesar A Moran
Journal:  Am J Clin Pathol       Date:  2008-11       Impact factor: 2.493

2.  Biomarkers and prognostic factors for mesothelioma.

Authors:  Harvey I Pass
Journal:  Ann Cardiothorac Surg       Date:  2012-11

3.  Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients.

Authors:  D J Sugarbaker; R M Flores; M T Jaklitsch; W G Richards; G M Strauss; J M Corson; M M DeCamp; S J Swanson; R Bueno; J M Lukanich; E H Baldini; S J Mentzer
Journal:  J Thorac Cardiovasc Surg       Date:  1999-01       Impact factor: 5.209

Review 4.  Challenges and controversies in the diagnosis of malignant mesothelioma: Part 2. Malignant mesothelioma subtypes, pleural synovial sarcoma, molecular and prognostic aspects of mesothelioma, BAP1, aquaporin-1 and microRNA.

Authors:  Douglas W Henderson; Glen Reid; Steven C Kao; Nico van Zandwijk; Sonja Klebe
Journal:  J Clin Pathol       Date:  2013-07-06       Impact factor: 3.411

5.  Pleomorphic epithelioid diffuse malignant pleural mesothelioma: a clinicopathological review and conceptual proposal to reclassify as biphasic or sarcomatoid mesothelioma.

Authors:  Kyuichi Kadota; Kei Suzuki; Camelia S Sima; Valerie W Rusch; Prasad S Adusumilli; William D Travis
Journal:  J Thorac Oncol       Date:  2011-05       Impact factor: 15.609

Review 6.  Diffuse malignant mesothelioma.

Authors:  Sergio Pina Oviedo; Philip T Cagle
Journal:  Arch Pathol Lab Med       Date:  2012-08       Impact factor: 5.534

7.  Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group.

Authors:  Aliya N Husain; Thomas Colby; Nelson Ordonez; Thomas Krausz; Richard Attanoos; Mary Beth Beasley; Alain C Borczuk; Kelly Butnor; Philip T Cagle; Lucian R Chirieac; Andrew Churg; Sanja Dacic; Armando Fraire; Francoise Galateau-Salle; Allen Gibbs; Allen Gown; Samuel Hammar; Leslie Litzky; Alberto M Marchevsky; Andrew G Nicholson; Victor Roggli; William D Travis; Mark Wick
Journal:  Arch Pathol Lab Med       Date:  2012-08-28       Impact factor: 5.534

8.  Morphometric profiling of lung cancers-its association with clinicopathologic, biologic, and molecular genetic features.

Authors:  Koji Okudela; Tetsukan Woo; Hideaki Mitsui; Takuya Yazawa; Hiroaki Shimoyamada; Michihiko Tajiri; Nobuo Ogawa; Munetaka Masuda; Hitoshi Kitamura
Journal:  Am J Surg Pathol       Date:  2010-02       Impact factor: 6.394

9.  Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis.

Authors:  Noriko Motoi; Janos Szoke; Gregory J Riely; Venkatraman E Seshan; Mark G Kris; Valerie W Rusch; William L Gerald; William D Travis
Journal:  Am J Surg Pathol       Date:  2008-06       Impact factor: 6.394

10.  Lower- and higher-grade subtypes of diffuse gastric cancer.

Authors:  Anna Maria Chiaravalli; Catherine Klersy; Francesca Tava; Rachele Manca; Roberto Fiocca; Carlo Capella; Enrico Solcia
Journal:  Hum Pathol       Date:  2009-06-21       Impact factor: 3.466

View more
  4 in total

Review 1.  Radical multimodality therapy for malignant pleural mesothelioma.

Authors:  Omar Abdel-Rahman; Zeinab Elsayed; Hadeer Mohamed; Mostafa Eltobgy
Journal:  Cochrane Database Syst Rev       Date:  2018-01-08

2.  Biomarkers for Early Diagnosis and Prognosis of Malignant Pleural Mesothelioma: The Quest Goes on.

Authors:  Caterina Ledda; Paola Senia; Venerando Rapisarda
Journal:  Cancers (Basel)       Date:  2018-06-15       Impact factor: 6.639

Review 3.  Current Management and Future Perspective in Pleural Mesothelioma.

Authors:  Rajiv Shah; Laura V Klotz; Julia Glade
Journal:  Cancers (Basel)       Date:  2022-02-18       Impact factor: 6.639

4.  Nucleolin and nucleophosmin expression patterns in pulmonary adenocarcinoma invading the pleura and in pleural malignant mesothelioma.

Authors:  Marek Masiuk; Piotr Waloszczyk; Magdalena Lewandowska; Ewa Dobak; Elzbieta Urasinska
Journal:  Thorac Cancer       Date:  2020-07-16       Impact factor: 3.500

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.